Skip to main content
. 2024 Apr 23;48(5):915–928. doi: 10.4093/dmj.2023.0259

Table 1.

Baseline characteristics of the participants

Variable Group
P value
Total (n=214) Alo (n=75) Pio (n=69) Alo+Pio (n=70)
Age, yr 58.9±9.2 58.9±8.7 58.12±9.9 59.7±9.0 0.6822a
Age <65 year 144 (67.29) 55 (73.33) 45 (65.22) 44 (62.86) 0.3671
Male sex 122 (57.01) 44 (58.67) 41 (59.42) 37 (52.86) 0.6907
Weight, kg 67.4±11.2 67.8±11.7 69.3±11.3 65.2±10.2 0.1555a
BMI, kg/m2 25.4±3.3 25.5±3.3 25.7±3.3 25.1±3.4 0.4418a
Duration of T2DM, yr 9.1±5.7 9.6 ± 5.6 8.1± 5.6 9.7± 5.8 0.1295a
Metformin dose, mg/day 1,434.8±353.1 1,416.0±361.3 1,476.1±339.4 1,414.3±358.9 0.5226a
Hypertension 128 (59.81) 48 (64.00) 40 (57.97) 40 (57.14) 0.6531
Dyslipidemia 169 (78.97) 61 (81.33) 51 (73.91) 57 (81.43) 0.4562
Current smoker 34 (15.89) 10 (13.33) 14 (20.29) 10 (14.29) 0.7615
Alcohol 96 (44.86) 34 (45.33) 26 (37.68) 36 (51.43) 0.2638
HbA1c, % 8.0±0.4 7.9±0.7 8.1±0.8 8.1±0.8 0.3238a
FBS, mg/dL 160.1±38.4 155.8±36.3 159.3±41.8 165.5±36.9 0.0069a
Fasting C-peptide, ng/dL 1.72±0.75 1.73±0.74 1.79±0.89 1.64±0.61 0.7908a
Glycoalbumin, % 20.3±3.7 19.8±3.5 20.1±3.9 20.9±3.8 0.2220b
GA/HbA1c ratio 2.5±0.4 2.5±0.3 2.5±0.4 2.6±0.4 0.3105b
Total cholesterol, mg/dL 163.6±37.4 163.5±33.3 157.7±34.4 169.4±43.6 0.3751a
Triglyceride, mg/dL 170.4±262.5 163.9±151.9 137.4±68.7 210.0±425.0 0.2791a
HDL-C, mg/dL 51.6±11.7 50.3±11.0 52.9±13.5 51.8±10.6 0.4817a
LDL-C, mg/dL 94.5±30.6 96.3±32.1 91.0±29.8 96.0±30.1 0.4464a

Values are presented as mean±standard deviation or number (%).

Alo, alogliptin; Pio, pioglitazone; BMI, body mass index; T2DM, type 2 diabetes mellitus; HbA1c, glycosylated hemoglobin; FBS, fasting blood sugar; GA, glycoalbumin; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol.

a

Kruskal-Wallis test for nonparametric statistical analysis,

b

Analysis of variance (ANOVA) test for parametric analysis.